A Prospective Evaluation of the Analytical Performance of GENECUBE® HQ SARS-CoV-2 and GENECUBE® FLU A/B
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.02.24.21252337: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The ethics committee of TMCH approved the present study (approval number: 2020-046), and informed consent was obtained from patients for their participation in the part of the current research using fresh samples.
Consent: The ethics committee of TMCH approved the present study (approval number: 2020-046), and informed consent was obtained from patients for their participation in the part of the current research using fresh samples.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not …
SciScore for 10.1101/2021.02.24.21252337: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The ethics committee of TMCH approved the present study (approval number: 2020-046), and informed consent was obtained from patients for their participation in the part of the current research using fresh samples.
Consent: The ethics committee of TMCH approved the present study (approval number: 2020-046), and informed consent was obtained from patients for their participation in the part of the current research using fresh samples.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Several limitations associated with the present study should be mentioned. First, we did not evaluate anterior nasal or saliva samples. Sample collection from the anterior nasal cavity or saliva is less invasive than that from the nasopharynx [27,28], and several molecular examinations can adequately detect SARS-CoV-2 in these samples [28,29]. Further research is warranted to evaluate the performance of GENECUBE® HQ SARS-CoV-2 using samples collected from body sites other than the nasopharynx. Second, the analytical performance may be affected by the future emergence of mutations SARS-CoV-2 and the influenza virus which are involved in the target areas of GENECUBE® HQ SARS-CoV-2 and GENECUBE® FLU A/B. Finally, the data for GENECUBE® FLU A/B were limited due to the low prevalence of the influenza virus, especially for fresh samples. In conclusion, GENECUBE® HQ SARS-CoV-2 and the GENECUBE® FLU A/B provided high analytical performance and the ability to evaluate multiple samples in a short period of time.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
